Eir Ventures Closes Life Science Venture Fund at EUR122 million
New Nordic fund focused on high-impact medical innovation
Nine…
eTheRNA immunotherapies conference attendance from December 2021 to March 2022
eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage…
Merck KGaA, Darmstadt, Germany, Expands Corporate Venture Fund M Ventures with a New Investment of € 600 Million
Merck KGaA, Darmstadt, Germany, a leading science and technology…
Biocomposites Signs Distribution Agreement with NuVasive Specialized Orthopedics to supply STIMULAN® in Germany
STIMULAN® is the first and only calcium matrix approved as an…
ISA to present key learnings for cancer vaccine development at the ESMO Immuno-Oncology Congress
Oegstgeest, December 7, 2021 – ISA’s very own Chief Scientific…
ATP Launches Adendra Therapeutics, a New Kind of Immunotherapy Company Deploying Novel Insights into Dendritic Cell Biology, with $53M Series A
Co-founded with renowned immunologist Professor Caetano Reis…
Exact Therapeutics AS Appoints Prominent Ultrasound And Healthcare Expert To Its Board Of Directors
Underscores the Company’s ambition to harness the power of…
Leucid Bio and Lonza Enter Strategic Collaboration to Leverage the Cocoon® Platform for Automated Manufacturing of Personalised CAR T-Cells
Leucid will work with Lonza on the Cocoon® Platform for…
ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors
Seasoned biotech executive with a wealth of experience and a…
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders
Building the team with experienced biotech experts and renowned…
Synaffix Announces Expansion of Mersana License Deal to a Total Potential Value Exceeding $1 Billion
Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific…
Joint Development Agreement with 4basebio PLC for novel CAR T-cell production methods
Leucid Bio: Joint Development Agreement with 4basebio PLC for…
EXACT THERAPEUTICS AS PROVIDES STRATEGIC BUSINESS UPDATE
Plans to recommence enrolment in the ACTIVATE clinical trial…
Calliditas Interim Report Q3, 2021
A quarter of deal making and regulatory review
“Following…
Novo Holdings and Lundbeckfonden Portfolio Company IO Biotech Closes Initial Public Offering on the Nasdaq Global Market
Incubated and supported by Denmark’s largest biotech investors,…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
